Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-hB7.1 + recombinant interferon gamma
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intraperitoneal
01
Overview
ALVAC-hB7.1 + recombinant interferon gamma is an experimental combination immunotherapy developed by the National Cancer Institute (NCI) for the treatment of refractory epithelial ovarian cancer. The regimen involves the intraperitoneal administration of an autologous tumor cell vaccine and recombinant interferon gamma (rIFN-gamma). The vaccine component, ALVAC-hB7.1, utilizes a recombinant canarypox virus vector to deliver the human B7.1 (CD80) gene into the patient's own tumor cells, which are then reintroduced to provide costimulatory signals to T cells. Recombinant interferon gamma is a potent cytokine that enhances the expression of Major Histocompatibility Complex (MHC) class I and II molecules on tumor cells and activates macrophages and natural killer cells. By delivering these agents directly into the peritoneal cavity, the therapy aims to stimulate a localized, robust anti-tumor immune response in patients with advanced ovarian cancer.
- Other names
- ALVAC-hB7.1 Vaccine and IFN-gamma in Ovarian CancerALVAC-hB-7.1 Vaccine and IFN-gamma in Ovarian CancerALVAC-hB 7.1 Vaccine and IFN-gamma in Ovarian Cancer
02
Targets
CD28 (Cluster of Differentiation 28)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on ALVAC-hB7.1 + recombinant interferon gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-hB7.1 + recombinant interferon gamma.